Loading
EP
ESSA Pharma Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Parkinson David Ross, was filed 18 Dec 2023.
ESSA Pharma Inc.: what insiders have been doing
Every trade that managers of ESSA Pharma Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. ESSA Pharma Inc. has had no insider filing for more than a year; the last one goes back to 15 October 2025.
Over the whole record (from 2016), the tally stands at 53 purchases and 33 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
160
Thresholds
n/a
Buy Volume
€17M
53 ops. · all time
Sell Volume
€13M
33 ops. · all time
Who traded when
BuySaleGrowth N. Biotech V4 sales
BVF Partners L P/il3 sales
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended September 2024 · cache
Income statement
Net income-US$24.6M
Last declaration on 15 October 2025
Declarations160 total
65,675 sharesCommon SharesSEC:0001104659-25-099659:0
33,343 sharesCommon SharesSEC:0001104659-25-099657:0
784,404 sharesCommon SharesSEC:0001104659-25-099655:0
43,240 sharesCommon SharesSEC:0001104659-25-099652:0
30,002 sharesCommon SharesSEC:0001104659-25-099650:0
14,299 sharesCommon SharesSEC:0001104659-25-099647:0
2,881 sharesCommon SharesSEC:0001104659-25-099644:0
6,194,145 sharesCommon StockSEC:0000921895-25-002742:0
4,726,743 sharesCommon StockSEC:0000921895-25-002742:1
560,797 sharesCommon StockSEC:0000921895-25-002742:2
203,336 sharesCommon StockSEC:0000921895-25-002133:2
1,235,030 shares21.9% of flowCommon StockSEC:0000921895-25-002133:1
79 shares@ US$1.877926.3% of flowCommon StockSEC:0000921895-25-002133:3
66 shares@ US$1.877922.0% of flowCommon StockSEC:0000921895-25-002133:4
11 shares@ US$1.87793.7% of flowCommon StockSEC:0000921895-25-002133:5
1,481,634 shares100.0% of flowCommon StockSEC:0000921895-25-002133:0
2,000,000 shares@ US$1.53213.5% of flowCommon SharesSEC:0000950170-24-121206:0
2,000,000 shares@ US$1.525913.4% of flowCommon SharesSEC:0000950170-24-121206:1
2,000,000 shares@ US$1.529413.5% of flowCommon SharesSEC:0000950170-24-121206:2
1,879,583 shares@ US$1.51312.5% of flowCommon SharesSEC:0000950170-24-121206:3
694 shares@ US$6.031.4% of flowCommon SharesSEC:0000950170-24-113174:0
694 shares@ US$6.001.4% of flowCommon SharesSEC:0000950170-24-104661:0
694 shares@ CA$6.00Common SharesTSXSEDI:4372789
2,082 shares@ US$6.034.2% of flowCommon SharesSEC:0000950170-24-103055:0
2,082 shares@ CA$6.03Common SharesTSXSEDI:4369030
25 of 160 declarations
About ESSA Pharma Inc.
ESSA Pharma Inc. is a clinical-stage biopharmaceutical company that historically focused on developing novel therapies for prostate cancer. The company was founded in 2009 and built its scientific identity around targeting the androgen receptor N-terminal domain, a differentiated mechanism of action versus conventional anti-androgen approaches. While its operational roots have been tied to Vancouver, ESSA has also been a U.S.-market name through its NASDAQ listing under ticker EPIX in the United States, which placed it on the radar of investors following SEC filings, including Form 4 insider transactions.
From a business-model perspective, ESSA has been a highly focused oncology developer rather than a diversified pharmaceutical platform. Its core effort centered on small-molecule drug development for androgen receptor–driven prostate cancer, with masofaniten (EPI-7386) becoming its best-known clinical asset. That program was designed to be evaluated both as monotherapy and in combination with enzalutamide, reflecting ESSA’s strategy of addressing disease settings where standard-of-care therapies have limited durability. For investors, this has positioned the company as a classic high-risk, high-science biotech story: potentially meaningful differentiation if the mechanism translated clinically, but with substantial dependence on trial execution and regulatory milestones.
Read moreShow less
ESSA’s competitive positioning came from scientific specificity rather than scale. In prostate cancer, competition is intense and includes large-cap pharmaceutical companies, established oncology franchises, and numerous development-stage biotech peers. ESSA’s value proposition was therefore rooted in the hope that targeting the AR N-terminal domain could help address resistance mechanisms in advanced prostate cancer, particularly in patients whose disease had progressed after exposure to modern anti-androgen agents. That niche focus made the company interesting to specialists, but also vulnerable to clinical readouts and financing constraints typical of pre-commercial biotech firms.
Recent developments materially changed the investment case. SEC Form 4 filings from October 2025 indicate that a business combination resulted in the acquisition of all outstanding common shares, with consideration of approximately US$0.12 per share plus one contingent value right per share that could pay up to approximately US$0.14 per CVR. In practical terms, this points to ESSA moving away from life as an independent NASDAQ-listed development-stage issuer and toward a transaction-driven wind-down or monetization event. For equity analysts, that means ESSA should now be viewed less as an active growth biotechnology story and more as a case of corporate action and final value realization in the United States market.
